Abstract
M2-M3 linkers are receptor subunit domains known to be critical for the normal function of cysteine-loop ligand-gated ion channels. Previous studies of α and β subunits of type “A” GABA receptors suggest that these linkers couple extracellular elements involved in GABA binding to the transmembrane segments that control the opening of the ion channel. To study the importance of the γ subunit M2-M3 linker, we examined the macroscopic and single-channel effects of an engineered γ2(L287A) mutation on GABA activation and propofol modulation. In the macroscopic analysis, we found that the γ2(L287A) mutation decreased GABA potency but increased the ability of propofol to enhance both GABA potency and efficacy compared with wild-type receptors. Indeed, although propofol had significant effects on GABA potency in wild-type receptors, we found that propofol produced no corresponding increase in GABA efficacy. At the single-channel level, mutant receptors showed a loss in the longest of three open-time components compared with wild-type receptors under GABA activation. Furthermore, propofol reduced the duration of one closed-time component, increased the duration of two open-time components, and generated a third open component with a longer lifetime in mutant compared with wild-type receptors. Taken together, we conclude that although the γ subunit is not required for the binding of GABA or propofol, the M2-M3 linker of this subunit plays a critical role in channel gating by GABA and allosteric modulation by propofol. Our results also suggest that in wild-type receptors, propofol exerts its enhancing effects by mechanisms extrinsic to channel gating.
Footnotes
- Received February 2, 2009.
- Accepted June 24, 2009.
This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grant GM073959].
ABBREVIATIONS: PRO, propofol; GABAAR, type A GABA receptor; WT, wild-type α1β1γ2 GABAAR; MUT, mutant α1β1γ2(L278A) type A GABA receptor; M2-M3 linker, extracellular domain joining transmembrane domains 2 and 3; LGIC, ligand-gated ion channel; DMEM, Dulbecco's modified Eagle's medium; ϵ, relative efficacy; tcrit, critical time; C, closed; O, open.
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
↵1 Current affiliation: Department of Molecular Neurogenetics, Max Planck Institute of Biophysics, Frankfurt am Main, Germany.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|